1. Cell Cycle/DNA Damage
  2. DNA Alkylator/Crosslinker
  3. Carmustine

カルムスチン  (Synonyms: Carmustine)

製品番号: HY-13585 純度: 99.91%
COA 取扱説明書 Technical Support

Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 154-93-8

容量 価格(税別) 在庫状況 数量
Solid or liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 33 在庫あり
Solution
10 mM * 1 mL in DMSO USD 33 在庫あり
Solid or liquid
5 mg $30 在庫あり
10 mg $50 在庫あり
25 mg $65 在庫あり
50 mg $80 在庫あり
100 mg $135 在庫あり
200 mg $200 在庫あり
500 mg $370 在庫あり
1 g   お問い合わせ  
5 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 10 publication(s) in Google Scholar

Other Forms of Carmustine:

Top Publications Citing Use of Products

    Carmustine purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2026 Mar;117(3):695-710.  [Abstract]

    RV increases the sensitivity of GBM cells to chemotherapeutic agents. Graphs show GBM cell viability after 48 h treatment with 50 μM RV combined with 50 μM TMZ or 50 μM Carmustine (BCNU), compared to DMSO and untreated controls (Ctrl).

    Carmustine purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Sep;26(9):1545-1557.

    C57BL/6J mice bearing GSDME-overexpressing murine melanoma B16 cell-derived xenografts were treated intraperitoneally with Carmustine (20 mg/kg) and RSL3 (10 mg/kg) daily for 1 week. Xenograft tumours and their corresponding tumour weights are indicated (n = 7). PBS was used as a control. The results demonstrated that the combination of Carmustine and RSL3 effectively suppressed tumor growth.

    Carmustine purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Sep;26(9):1545-1557.

    RSL3 (100 nM) combined with different reagents, including MMS (methyl methanesulfonate, 1 mM), MNNG (N-methyl-N’-nitro-N’-nitrosoguanidine, 0.3 mM) and Carmustine (0.25 mM)), were used to treated cells, the pyroptotic morphologies were observed. RSL3 combined with lower dose of UVC irradiation (50 mJ cm-2) was used as a positive control.

    Carmustine purchased from MedChemExpress. Usage Cited in: Biomaterials. 2022 May;284:121533.  [Abstract]

    Quantitative analysis of intracellular GSH using flow cytometry. Carmustine was used as positive control. ROS and GSH analysis were performed with 4T1 cells upon treatment for 6 h.

    Carmustine purchased from MedChemExpress. Usage Cited in: J Drug Deliv Sci Technol. 9 September 2022, 103770.

    Dose response curves of free drugs and drug-loaded nanoparticles. In vitro cell viability assays of U251 cells after 48 h of incubation with Carmustine (BCNU, 62.5-500 μM), BCNU-loaded Fe3O4@MIL-88B–NH2 nanocomposites.
    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.

    IC50 & Target

    DNA Alkylator[1]

    Cellular Effect
    Cell Line Type Value Description References
    A 172 IC50
    18 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A 172 IC50
    18 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A 172 IC50
    18 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A-427 IC50
    8 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A-427 IC50
    8 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A-427 IC50
    8 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A498 IC50
    110 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A498 IC50
    110 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A498 IC50
    110 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A549 IC50
    90 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A549 IC50
    90 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    A549 IC50
    90 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    Astrocyte EC50
    54.8 3
    Compound: 1, BCNU, Carmustine
    Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method
    Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method
    10.1007/s00044-010-9356-8
    Astrocyte EC50
    54.8 3
    Compound: 1, BCNU, Carmustine
    Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method
    Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method
    10.1007/s00044-010-9356-8
    Astrocyte EC50
    54.8 3
    Compound: 1, BCNU, Carmustine
    Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method
    Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method
    10.1007/s00044-010-9356-8
    Astrocyte IC50
    155.6 3
    Compound: BCNU
    Cytotoxicity against rat astrocytes
    Cytotoxicity against rat astrocytes
    [PMID: 16970409]
    Astrocyte IC50
    155.6 3
    Compound: BCNU
    Cytotoxicity against rat astrocytes
    Cytotoxicity against rat astrocytes
    [PMID: 16970409]
    C6 EC50
    4.8 3
    Compound: 1, BCNU, Carmustine
    Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method
    Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method
    10.1007/s00044-010-9356-8
    C6 EC50
    4.8 3
    Compound: 1, BCNU, Carmustine
    Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method
    Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method
    10.1007/s00044-010-9356-8
    C6 EC50
    4.8 3
    Compound: 1, BCNU, Carmustine
    Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method
    Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method
    10.1007/s00044-010-9356-8
    CCD 19Lu IC50
    300 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    C6 IC50
    9.3 3
    Compound: BCNU
    Cytotoxicity against rat C6 glioma cell line
    Cytotoxicity against rat C6 glioma cell line
    [PMID: 16970409]
    C6 IC50
    9.3 3
    Compound: BCNU
    Cytotoxicity against rat C6 glioma cell line
    Cytotoxicity against rat C6 glioma cell line
    [PMID: 16970409]
    DOD-1 IC50
    37 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    CCD 19Lu IC50
    300 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    HL-60 IC50
    30.5 3
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay
    10.1007/s00044-011-9778-y
    CCD 19Lu IC50
    300 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    CHO IC50
    8.2 3
    Compound: Carmustine
    Dose required to inhibit cell growth was determined against CHO cell line
    Dose required to inhibit cell growth was determined against CHO cell line
    [PMID: 11262080]
    L1210 ED50
    4 3
    Compound: BCNU
    Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis
    Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis
    [PMID: 563461]
    DOD-1 IC50
    37 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    LOX IMVI IC50
    7 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    HL-60 IC50
    30.5 3
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay
    10.1007/s00044-011-9778-y
    Malme-3M IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    DOD-1 IC50
    37 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    MCF7 IC50
    4.5 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    NCH89 IC50
    615 3
    Compound: Carmustine
    Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs
    Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs
    [PMID: 20329733]
    HL-60 IC50
    30.5 3
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay
    10.1007/s00044-011-9778-y
    HT-29 IC50
    17 3
    Compound: Carmustine
    Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma
    Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma
    [PMID: 11262080]
    L1210 ED50
    20 31
    Compound: Table III, R37C1
    Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days
    Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days
    [PMID: 836500]
    NCI/ADR-RES IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    L1210 ED50
    4 3
    Compound: BCNU
    Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice.
    Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice.
    [PMID: 2939245]
    K562 IC50
    9 3
    Compound: Carmustine
    Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia
    Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia
    [PMID: 11262080]
    NCI-H125 IC50
    9 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    L1210 ED50
    20 31
    Compound: Table III, R37C1
    Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days
    Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days
    [PMID: 836500]
    L1210 ED50
    4 3
    Compound: BCNU
    Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis
    Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis
    [PMID: 563461]
    NCI-H23 IC50
    5 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    L1210 ED50
    4 3
    Compound: BCNU
    In vitro inhibitory activity against murine leukemia L1210 cells
    In vitro inhibitory activity against murine leukemia L1210 cells
    [PMID: 6256551]
    L1210 ED50
    4 3
    Compound: BCNU
    Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice.
    Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice.
    [PMID: 2939245]
    NCI-H322M IC50
    60 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    L1210 ED50
    4 3
    Compound: BCNU
    Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis
    Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis
    [PMID: 563461]
    L1210 IC50
    4.5 3
    Compound: Carmustine
    Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia
    Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia
    [PMID: 11262080]
    NCI-H358 IC50
    98 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    LOX IMVI IC50
    7 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    L1210 ED50
    4000 1
    Compound: BCNU
    In vitro inhibitory activity against murine leukemia L1210 cells
    In vitro inhibitory activity against murine leukemia L1210 cells
    [PMID: 6256551]
    NCI-H460 IC50
    80 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    L1210 IC50
    4.5 3
    Compound: Carmustine
    Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia
    Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia
    [PMID: 11262080]
    Malme-3M IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H520 IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    MCF7 IC50
    4.5 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    OVCAR-3 IC50
    15 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    OVCAR-4 IC50
    18 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    NCH89 IC50
    615 3
    Compound: Carmustine
    Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs
    Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs
    [PMID: 20329733]
    SF-126 IC50
    20 3
    Compound: BCNU
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
    [PMID: 27041398]
    NCI/ADR-RES IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    SF-126 IC50
    25 3
    Compound: BCNU
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
    [PMID: 27041398]
    NCI-H125 IC50
    9 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    SF-126 IC50
    55 3
    Compound: BCNU
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
    [PMID: 28197307]
    SF-126 IC50
    85 3
    Compound: BCNU
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    [PMID: 28197307]
    NCI-H23 IC50
    5 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H322M IC50
    60 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    SK-MEL-5 IC50
    27 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    TE-671 IC50
    25 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H358 IC50
    98 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H460 IC50
    80 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    U-251 IC50
    15 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H520 IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    U-87MG ATCC IC50
    1.42 3
    Compound: BCNU
    In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr
    In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr
    [PMID: 15603970]
    OVCAR-3 IC50
    15 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    U-87MG ATCC IC50
    3.9 6
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay
    10.1007/s00044-012-0249-x
    U-87MG ATCC IC50
    3.9 6
    Compound: Carmustine
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay
    [PMID: 33276991]
    OVCAR-4 IC50
    18 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    U-937 IC50
    12.3 3
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay
    10.1007/s00044-011-9778-y
    LOX IMVI IC50
    7 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    MCF7 IC50
    4.5 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    SF-126 IC50
    85 3
    Compound: BCNU
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    [PMID: 28197307]
    SF-126 IC50
    55 3
    Compound: BCNU
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
    [PMID: 28197307]
    MDA-MB-231 IC50
    7.4 3
    Compound: Carmustine
    Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma
    Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma
    [PMID: 11262080]
    SF-126 IC50
    20 3
    Compound: BCNU
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
    [PMID: 27041398]
    SF-126 IC50
    25 3
    Compound: BCNU
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
    [PMID: 27041398]
    Malme-3M IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    NCH89 IC50
    615 3
    Compound: Carmustine
    Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs
    Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs
    [PMID: 20329733]
    SK-MEL-5 IC50
    27 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H125 IC50
    9 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H23 IC50
    5 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    TE-671 IC50
    25 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    U-251 IC50
    15 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H322M IC50
    60 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    NCI-H358 IC50
    98 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    U-87MG ATCC IC50
    3.9 3
    Compound: Carmustine
    Antiproliferative activity against human U87 cells
    Antiproliferative activity against human U87 cells
    [PMID: 33421712]
    NCI-H460 IC50
    80 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    U-87MG ATCC IC50
    3.9 6
    Compound: Carmustine
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay
    [PMID: 33276991]
    NCI-H520 IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
    [PMID: 2391696]
    U-87MG ATCC IC50
    3.9 6
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay
    10.1007/s00044-012-0249-x
    NCI/ADR-RES IC50
    20 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    U-87MG ATCC IC50
    1.42 3
    Compound: BCNU
    In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr
    In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr
    [PMID: 15603970]
    U-937 IC50
    12.3 3
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay
    10.1007/s00044-011-9778-y
    OVCAR-3 IC50
    15 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    OVCAR-4 IC50
    18 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    P388 ED50
    13.3 3
    Compound: BCNU
    Mean value for the exposure for P388 to the drug for a period of 60 min
    Mean value for the exposure for P388 to the drug for a period of 60 min
    [PMID: 6226795]
    P388 ED50
    6.3 3
    Compound: BCNU
    Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree
    Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree
    [PMID: 6226795]
    P388 IC50
    5.9 3
    Compound: Carmustine
    Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia
    Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia
    [PMID: 11262080]
    SF-126 IC50
    20 3
    Compound: BCNU
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
    [PMID: 27041398]
    SF-126 IC50
    25 3
    Compound: BCNU
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
    Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
    [PMID: 27041398]
    SF-126 IC50
    55 3
    Compound: BCNU
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
    [PMID: 28197307]
    SF-126 IC50
    85 3
    Compound: BCNU
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    [PMID: 28197307]
    SK-MEL-5 IC50
    27 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    Sf21 IC50
    > 1000 3
    Compound: Carmustine
    Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
    Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
    [PMID: 21965623]
    Sf21 IC50
    > 1000 3
    Compound: Carmustine
    Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
    Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
    [PMID: 21965623]
    TE-671 IC50
    25 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    U-251 IC50
    15 3
    Compound: BCNU
    Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
    [PMID: 2391696]
    U-87MG ATCC IC50
    1.42 3
    Compound: BCNU
    In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr
    In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr
    [PMID: 15603970]
    U-87MG ATCC IC50
    3.9 3
    Compound: Carmustine
    Antiproliferative activity against human U87 cells
    Antiproliferative activity against human U87 cells
    [PMID: 33421712]
    U-87MG ATCC IC50
    3.9 6
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay
    10.1007/s00044-012-0249-x
    U-87MG ATCC IC50
    3.9 6
    Compound: Carmustine
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay
    [PMID: 33276991]
    U-937 IC50
    12.3 3
    Compound: BCNU
    Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay
    10.1007/s00044-011-9778-y
    体外実験

    Carmustine is an antitumor chemotherapeutic agent. Carmustine (8, 80, and 800 μM) decreases N-acetyltransferase (NAT) activities for 2-aminofluorene (AF) and p-aminobenzoic acid (PABA) in rat glial tumor cytosol and intact cells. In rat glial tumor cells, the DNA-AF adduct increases, and carmustine decreases the formation of DNA-AF adduct[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    体内実験

    Carmustine (BCNU; 25 mg/kg, i.p.) causes higher levels of the rhe ratio of liver weight to body weight and plasma conjugated bilirubin, and lower biliary flow, oxidised glutation levels (GSSG) and reduced glutation (GSH)/GSSG values compared with control rats[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    臨床実験
    分子量

    214.05

    分子式

    C5H9Cl2N3O2

    CAS 番号
    Appearance

    <30°C Solid,>30°C Liquid

    Color

    White to yellow

    SMILES

    O=C(NCCCl)N(CCCl)N=O

    輸送条件

    Room temperature in continental US; may vary elsewhere.

    保管条件

    -20°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶剤 & 溶解度
    体外: 

    DMSO : 100 mg/mL (467.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 100 mg/mL (467.18 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.6718 mL 23.3590 mL 46.7181 mL
    5 mM 0.9344 mL 4.6718 mL 9.3436 mL
    10 mM 0.4672 mL 2.3359 mL 4.6718 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始)

    C1

    ×
    体積 (開始)

    V1

    =
    濃度 (終了)

    C2

    ×
    体積 (終了)

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (9.72 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (9.72 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 100 mg/mL (467.18 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    純度とドキュメンテーション

    純度: 99.91%

    参考文献
    キナーゼ実験
    [1]

    The determination of Acetyl-CoAdependent N-acetylation of 2-aminofluorene (AF) and p-aminobenzoic acid (PABA) are performed. Incubation mixtures in the assay system consists of a total volume of 90 μL: glial tumor cells cytosols, diluted as required, in 50 μL of lysis buffer (20 mM Tris/HCl, pH 7.5, 1 mM DTT and 1 mM EDTA), 20 μL of an Acetyl-CoA recycling mixture of 50 mM Tris-HCl (pH7.5), 0.2 mM EDTA, 2 mM DTT, 15 mM acetylcamitine, 2U/mL carnitine acetyltransferase, and AF or PABA at specific concentrations. The reactions are started by addition of 20 μL of Acetyl-CoA. The control reactions have 20 μL distilled water in place of Acetyl-CoA. For the single point activity measurements, the final concentration of AF or PABA is 0.1 mM and AcCoA is 0.5 mM. The reaction mixtures with or without specific concentrations of Carmustine and lomustine are incubated at 37°C for 10 min and stopped with 50 μL of 20% trichloroacetic acid for the PABA reactions, and 100 μL of acetonitrile for the AF reactions. All of the reactions (experiments and controls) are run in triplicate[1].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。

    動物実験
    [2]

    Rats[2]
    Individual rats are weighted prior to enter the study; their weights are recorded, and they are randomLy assigned to four groups. Group I (saline group); This group consists of 12 rats. These rats are injected with 2 mL/kg of saline intraperitoneally (IP) 48 h before the study, being included by the study 48 h later. Group II (corn oil group) consists of 15 rats. These rats are injected with 2 mL/kg of corn oil (vehicle) IP 48 h before the study. Group III (Carmustine group) consists of 16 rats. These rats are injected with 1 mL per day of saline IP, administered at the same hour of the day as a single-dose for 3 days. Twelve hours after the first dose of saline, corn oil 2 mL/kg + Carmustine 25 mg/kg IP are injected, and the rats are included in the study 48 h after the administration of corn oil + Carmustine. Group IV (trimetazidine group) consists of 12 rats. These rats are injected with 2.5 mg/kg per day of trimetazidine (TMZ) IP, administered at the same hour of the day as a single-dose for 3 days. 12 h after the first dose of TMZ, corn oil 2 mL/kg + Carmustine 25 mg/kg IP are injected, and the rats are included in the study 48 h after the administration of corn oil + Carmustine[2].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。

    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 4.6718 mL 23.3590 mL 46.7181 mL 116.7951 mL
    5 mM 0.9344 mL 4.6718 mL 9.3436 mL 23.3590 mL
    10 mM 0.4672 mL 2.3359 mL 4.6718 mL 11.6795 mL
    15 mM 0.3115 mL 1.5573 mL 3.1145 mL 7.7863 mL
    20 mM 0.2336 mL 1.1680 mL 2.3359 mL 5.8398 mL
    25 mM 0.1869 mL 0.9344 mL 1.8687 mL 4.6718 mL
    30 mM 0.1557 mL 0.7786 mL 1.5573 mL 3.8932 mL
    40 mM 0.1168 mL 0.5840 mL 1.1680 mL 2.9199 mL
    50 mM 0.0934 mL 0.4672 mL 0.9344 mL 2.3359 mL
    60 mM 0.0779 mL 0.3893 mL 0.7786 mL 1.9466 mL
    80 mM 0.0584 mL 0.2920 mL 0.5840 mL 1.4599 mL
    100 mM 0.0467 mL 0.2336 mL 0.4672 mL 1.1680 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

     

    カスタマ需要量 *

    お名前 *

     

    タイトル

    メールアドレス *

     

    電話番号 *

    デパートメント

     

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

         

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Carmustine
    製品番号:
    HY-13585
    数量:
    MCE 日本正規代理店: